ALHC
Alignment Healthcare, Inc.
ALHC offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over ALHC overall, supported by stronger fundamentals and lower modeled downside.
ALHC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Under pressure | |
| Healthy |
ALHC's revenue, profitability and balance sheet are currently healthy, but its cash flow is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 42x | $5.83 | -22% |
| Current | 54x | $7.50 | — |
| Fair | 72x | $10.02 | +34% |
| Expensive | 199x | $27.91 | +272% |
| Forward | 1,075x | $7.50 | — |
Historical ranges are pointers, not guarantees.
ALHC's PE is 54x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ALHC in the historical PE scenario, which offers more potential upside but is not a forecast.
ALHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect ALHC to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ALHC on the outlook, with more favorable valuation and profitability expectations.
ALHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | -95% |
| Q3 2026 | $0.14 | +$0.25 |
| Q2 2026 | $0.20 | +$0.47 |
| Q1 2026 | $0.10 | +$0.57 |
| Q4 2025 | $0.00 | +$0.67 |
| Q3 2025 | -$0.11 | +$0.66 |
| Q2 2025 | -$0.27 | +$0.55 |
| Q1 2025 | -$0.47 | +$0.37 |
ALHC has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ALHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +37% |
| Q2 2026 | $1.3B | +32% |
| Q1 2026 | $1.2B | +33% |
| Q4 2025 | $1B | +44% |
| Q3 2025 | $993.7M | +44% |
| Q2 2025 | $1B | +49% |
| Q1 2025 | $926.9M | +47% |
| Q4 2024 | $701.2M | +51% |
ALHC's revenue has grown year over year every quarter since early 2021: $1.4B last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.3% | -1.1 points |
| Q2 2026 | 3.1% | +0.9 points |
| Q1 2026 | 1.3% | +1.8 points |
| Q4 2025 | -1% | +2.2 points |
| Q3 2025 | 0.8% | +3.6 points |
| Q2 2025 | 2.2% | +4.9 points |
| Q1 2025 | -0.6% | +6 points |
| Q4 2024 | -3.2% | +5.8 points |
ALHC's operating margin was −0.3% last quarter, down 1.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ALHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ALHC on profitability, with a higher operating margin.
ALHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.6M | -72% |
| Q2 2026 | -$27.5M | -230% |
| Q1 2026 | $121.3M | +1350% |
| Q4 2025 | -$55.4M | -$37.4M |
| Q3 2025 | $139.1M | +722% |
| Q2 2025 | $21.1M | +79% |
| Q1 2025 | $8.4M | +$25.7M |
| Q4 2024 | -$18M | +$169.5M |
ALHC generated $77M in free cash flow over the past year, down 49% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ALHC on cash flow, with more consistent year-over-year improvement.
ALHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3% | -6.5M shares |
| 1 year | -0.2% | -371K shares |
| 3 years | +11% | +19.9M shares |
| 5 years | +37% | +56.4M shares |
ALHC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | $1.5M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ALHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.4x | Net Cash |
| Q2 2026 | -4.3x | Net Cash |
| Q1 2026 | -5.8x | Net Cash |
| Q4 2025 | -5.6x | Net Cash |
| Q3 2025 | -9.3x | Net Cash |
| Q2 2025 | -34.5x | Net Cash |
| Q4 2020 | -5.6x | Net Cash |
ALHC has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ALHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.7 | Oversold |
| Stochastic | 13.9 | Oversold |
ALHC's weekly RSI is 30 (oversold) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ALHC PE vs Healthcare Sector
| Metric | ALHC | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 107% above |
| PE % | 29 | 36 | 7 pts below |
ALHC is trading at 54x earnings, a 107% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ALHC on valuation relative to its sector.
ALHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.77 | 3.5% below |
| 20 week MA | $12.5 | 40% below |
| 50 week MA | $16.7 | 55% below |
| 100 week MA | $16.0 | 53% below |
| 200 week MA | $11.9 | 37% below |
ALHC is in a downtrend: it's below all five of its weekly moving averages, and 37% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ALHC on trend strength, trading above more of its moving averages.
ALHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.3 | $13.7 | -21% |
| 2022 | $13.7 | $11.5 | -16% |
| 2023 | $11.5 | $8.61 | -25% |
| 2024 | $8.61 | $10.8 | +26% |
| 2025 | $10.8 | $18.8 | +74% |
| 2026 YTD | $18.8 | $7.50 | -60% |
ALHC has finished lower in three of the last five years. It's down 60% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ALHC on returns for 2026, with the stronger performance.